Bristol Myers Squibb

#Bristol Myers Squibb #Collaboration #Evotec #Neurodegenerative disorders #Neuroscience

Evotec and BMS enter drug discovery licence agreement

Evotec and Bristol Myers Squibb (BMS) have entered into an exclusive global licence agreement, extending their neuroscience partnership. The agreement covers selected late-stage discovery programmes that were developed and progressed within the collaboration between the two companies. Evotec and BMS originally entered their neurodegeneration… Read More

#News

Plaque psoriasis
#Bristol Myers Squibb #CHMP #Dermatology #European Medicines Agency #Phase III trial

First oral allosteric TYK2 inhibitor recommended in EU

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of Sotyktu (deucravacitinib) for the treatment of adults with moderate-to-severe plaque psoriasis.   Sotyktu, an oral medication taken once-daily, is a first-in-class, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment… Read More

#News #Regulatory